Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA \> 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months)~* Confirmed CPT class B (7-9) at screening~Exclusion Criteria:~* Current or prior history of solid organ transplantation, significant pulmonary disease, significant cardiac disease, or porphyria~* Inability to exclude hepatocellular carcinoma (HCC) by imaging within 6 months of baseline/Day 1~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Screening ECG with clinically significant abnormalities~* Prior exposure to SOF or any other nucleotide analogue HCV nonstructural protein 5B (NS5B) inhibitor or any HCV NS5A inhibitor~* Laboratory results outside of acceptable ranges at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL 12 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC for 12 weeks.
- SOF/VEL+RBV 12 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
- SOF/VEL 24 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).